Figure 2.
Proportion of genetic abnormalities in distinct gastric cancer subtypes. EBV: Epstein-Barr-positive; MSI: Microsatellite-instability; GS: Genomically stable; CIN: Chromosomal instability; PIK3CA/AKT: Phosphatidylinositol 3-kinase CA/AKT; HER2: Human epidermal growth factor receptor 2; HER3: Human epidermal growth factor receptor 3; FGFR2: Fibroblast growth factor receptor 2; KRAS: Kirsten rat sarcoma oncogene; MET: Mesenchymal-epithelial transition; JAK2: Janus kinase 2; PD-1/PD-L1: Programmed cell death-1/programmed cell death-ligand 1.